{"component": "clause", "props": {"groups": [{"size": 6, "snippet_links": [{"key": "preclinical-and-clinical-studies", "type": "clause", "offset": [8, 40]}, {"key": "behalf-of-the-company", "type": "clause", "offset": [60, 81]}, {"key": "by-the-company", "type": "clause", "offset": [170, 184]}, {"key": "to-the-company", "type": "definition", "offset": [189, 203]}, {"key": "by-third-parties", "type": "clause", "offset": [216, 232]}, {"key": "in-compliance-with", "type": "definition", "offset": [234, 252]}, {"key": "foreign-laws", "type": "definition", "offset": [286, 298]}, {"key": "orders-and-regulations", "type": "clause", "offset": [307, 329]}, {"key": "in-the-aggregate", "type": "definition", "offset": [445, 461]}, {"key": "material-adverse-effect", "type": "definition", "offset": [465, 488]}, {"key": "the-studies", "type": "clause", "offset": [494, 505]}, {"key": "clinical-trials", "type": "clause", "offset": [532, 547]}, {"key": "the-company-sec-documents", "type": "clause", "offset": [611, 636]}, {"key": "company-studies-and-trials", "type": "definition", "offset": [643, 669]}, {"key": "in-all-material-respects", "type": "definition", "offset": [721, 745]}, {"key": "in-accordance-with", "type": "clause", "offset": [746, 764]}, {"key": "procedures-and-controls", "type": "clause", "offset": [789, 812]}, {"key": "pursuant-to", "type": "clause", "offset": [813, 824]}, {"key": "where-applicable", "type": "clause", "offset": [826, 842]}, {"key": "results-of-the", "type": "clause", "offset": [912, 926]}, {"key": "contained-in", "type": "definition", "offset": [954, 966]}, {"key": "the-company-has", "type": "clause", "offset": [1032, 1047]}, {"key": "knowledge-of", "type": "definition", "offset": [1051, 1063]}, {"key": "other-studies", "type": "clause", "offset": [1068, 1081]}, {"key": "and-the-company", "type": "clause", "offset": [1266, 1281]}, {"key": "food-and-drug-administration", "type": "clause", "offset": [1352, 1380]}, {"key": "local-governmental-authority", "type": "definition", "offset": [1418, 1446]}, {"key": "the-termination", "type": "clause", "offset": [1489, 1504]}, {"key": "modification-of", "type": "clause", "offset": [1529, 1544]}, {"key": "reasonable-grounds", "type": "definition", "offset": [1739, 1757]}, {"key": "informed-consent", "type": "clause", "offset": [1824, 1840]}, {"key": "human-subject", "type": "definition", "offset": [1865, 1878]}, {"key": "clinical-investigator", "type": "definition", "offset": [2055, 2076]}, {"key": "the-fda", "type": "clause", "offset": [2098, 2105]}, {"key": "engaged-in", "type": "definition", "offset": [2114, 2124]}, {"key": "scientific-misconduct", "type": "definition", "offset": [2125, 2146]}, {"key": "facilities-and-operations", "type": "clause", "offset": [2194, 2219]}, {"key": "applicable-statutes", "type": "definition", "offset": [2298, 2317]}, {"key": "policies-of", "type": "definition", "offset": [2342, 2353]}, {"key": "governmental-authorities", "type": "definition", "offset": [2377, 2401]}, {"key": "outside-of-the-united-states", "type": "clause", "offset": [2402, 2430]}], "snippet": "(a) All preclinical and clinical studies conducted by or on behalf of the Company to support approval for commercialization of the Company\u2019s products have been conducted by the Company, or to the Company\u2019s knowledge by third parties, in compliance with all applicable federal, state or foreign laws, rules, orders and regulations, except for such failure or failures to be in compliance which would not reasonably be expected to have, singly or in the aggregate, a Material Adverse Effect.\n(b) The studies, tests and preclinical or clinical trials conducted by or on behalf of the Company that are described in the Company SEC Documents (the \u201cCompany Studies and Trials\u201d) were and, if still pending, are being, conducted in all material respects in accordance with experimental protocols, procedures and controls pursuant to, where applicable, accepted professional scientific standards; the descriptions of the results of the Company Studies and Trials contained in the Company SEC Documents are accurate in all material respects; the Company has no knowledge of any other studies or trials not described in the Company SEC Documents, the results of which are inconsistent with or call in question the results described or referred to in the Company SEC Documents; and the Company has not received any notices or correspondence from the United States Food and Drug Administration (the \u201cFDA\u201d) or any foreign, state or local governmental authority exercising comparable authority requiring the termination, suspension or material modification of any Company Studies and Trials that termination, suspension or material modification would reasonably be expected to have a Material Adverse Effect and, to the Company\u2019s knowledge, there are no reasonable grounds for the same. The Company has obtained (or caused to be obtained) informed consent by or on behalf of each human subject who participated in the Company Studies and Trials. To the Company\u2019s knowledge, none of the Company Studies and Trials involved any investigator who has been disqualified as a clinical investigator or has been found by the FDA to have engaged in scientific misconduct. To the Company\u2019s knowledge, the manufacturing facilities and operations of its suppliers are operated in compliance in all material respects with all applicable statutes, rules, regulations and policies of the FDA and comparable governmental authorities outside of the United States to which the Company is subject.", "samples": [{"hash": "a4alXQ52rHF", "uri": "/contracts/a4alXQ52rHF#development-matters", "label": "Collaboration and License Agreement (Neurocrine Biosciences Inc)", "score": 33.1101989746, "published": true}, {"hash": "k6hnf4YB02p", "uri": "/contracts/k6hnf4YB02p#development-matters", "label": "Stock Purchase Agreement (Voyager Therapeutics, Inc.)", "score": 30.1526355743, "published": true}, {"hash": "blku6Bo9ZuQ", "uri": "/contracts/blku6Bo9ZuQ#development-matters", "label": "Collaboration and License Agreement (Voyager Therapeutics, Inc.)", "score": 30.1526355743, "published": true}], "hash": "e926e6968d0c033ae7ebbda92cd77201", "id": 1}, {"size": 4, "snippet_links": [{"key": "the-studies", "type": "clause", "offset": [4, 15]}, {"key": "clinical-trials", "type": "clause", "offset": [42, 57]}, {"key": "behalf-of-the-company", "type": "clause", "offset": [77, 98]}, {"key": "the-company-sec-documents", "type": "clause", "offset": [121, 146]}, {"key": "company-studies-and-trials", "type": "definition", "offset": [153, 179]}, {"key": "to-the-company", "type": "definition", "offset": [215, 229]}, {"key": "being-conducted", "type": "definition", "offset": [243, 258]}, {"key": "in-all-material-respects", "type": "definition", "offset": [259, 283]}, {"key": "in-accordance-with", "type": "clause", "offset": [284, 302]}, {"key": "procedures-and-controls", "type": "clause", "offset": [327, 350]}, {"key": "results-of-the", "type": "clause", "offset": [434, 448]}, {"key": "contained-in", "type": "definition", "offset": [476, 488]}, {"key": "the-company-has", "type": "clause", "offset": [583, 598]}, {"key": "knowledge-of", "type": "definition", "offset": [602, 614]}, {"key": "other-studies", "type": "clause", "offset": [619, 632]}, {"key": "required-by", "type": "definition", "offset": [897, 908]}, {"key": "the-united-states", "type": "definition", "offset": [909, 926]}, {"key": "food-and-drug-administration", "type": "clause", "offset": [927, 955]}, {"key": "local-governmental-authority", "type": "definition", "offset": [1024, 1052]}, {"key": "health-care-facility", "type": "clause", "offset": [1089, 1109]}, {"key": "institutional-review-board", "type": "definition", "offset": [1110, 1136]}, {"key": "in-the-aggregate", "type": "definition", "offset": [1198, 1214]}, {"key": "material-adverse-effect", "type": "definition", "offset": [1226, 1249]}, {"key": "and-the-company", "type": "clause", "offset": [1251, 1266]}, {"key": "the-fda", "type": "clause", "offset": [1319, 1326]}, {"key": "the-termination", "type": "clause", "offset": [1423, 1438]}, {"key": "modification-of", "type": "clause", "offset": [1463, 1478]}], "snippet": "(a) The studies, tests and preclinical or clinical trials conducted by or on behalf of the Company that are described in the Company SEC Documents (the \u201cCompany Studies and Trials\u201d) were and, if still pending, are, to the Company\u2019s knowledge, being conducted in all material respects in accordance with experimental protocols, procedures and controls designed and approved for such Company Studies and Trials; the descriptions of the results of the Company Studies and Trials contained in the Company SEC Documents are, to the Company\u2019s knowledge, accurate in all material respects; the Company has no knowledge of any other studies or trials not described in the Company SEC Documents, the results of which are inconsistent with or call in question the results described or referred to in the Company SEC Documents; the Company has made all such filings and obtained all such approvals as may be required by the United States Food and Drug Administration (the \u201cFDA\u201d) or any committee thereof and from any foreign, state or local governmental authority exercising comparable authority, or health care facility Institutional Review Board, except as could not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect; and the Company has not received any notices or correspondence from the FDA or any foreign, state or local governmental authority exercising comparable authority requiring the termination, suspension or material modification of any Company Studies and Trials that termination, suspension or material modification would reasonably be expected to have a Material Adverse Effect.", "samples": [{"hash": "dLYMBMUYEk", "uri": "/contracts/dLYMBMUYEk#development-matters", "label": "Share Purchase Agreement (Xenon Pharmaceuticals Inc.)", "score": 30.9164962769, "published": true}, {"hash": "5VSjKCx0L3Q", "uri": "/contracts/5VSjKCx0L3Q#development-matters", "label": "License and Collaboration Agreement (Xenon Pharmaceuticals Inc.)", "score": 30.9164962769, "published": true}], "hash": "7a917d31be50c000b0474c3582985eec", "id": 2}, {"size": 4, "snippet_links": [{"key": "to-the-extent", "type": "clause", "offset": [0, 13]}, {"key": "required-by", "type": "definition", "offset": [14, 25]}, {"key": "applicable-law", "type": "clause", "offset": [26, 40]}, {"key": "the-mortgagee", "type": "clause", "offset": [42, 55]}, {"key": "obligation-to-file", "type": "clause", "offset": [79, 97]}, {"key": "cost-and-expense", "type": "clause", "offset": [145, 161]}, {"key": "the-execution", "type": "clause", "offset": [177, 190]}, {"key": "subdivision-plats", "type": "clause", "offset": [194, 211]}, {"key": "the-mortgaged-property", "type": "clause", "offset": [268, 290]}, {"key": "and-other-documents", "type": "clause", "offset": [291, 310]}, {"key": "with-respect-to", "type": "clause", "offset": [311, 326]}, {"key": "necessary-for", "type": "definition", "offset": [356, 369]}, {"key": "development-of-the", "type": "clause", "offset": [374, 392]}, {"key": "the-business-plan", "type": "clause", "offset": [431, 448]}, {"key": "provided-that", "type": "definition", "offset": [450, 463]}, {"key": "form-and-substance", "type": "clause", "offset": [539, 557]}, {"key": "in-all-respects", "type": "clause", "offset": [630, 645]}, {"key": "applicable-provisions-of-law", "type": "clause", "offset": [655, 683]}], "snippet": "To the extent required by applicable law, the Mortgagee, without incurring any obligation to file or record any documentation and at Mortgagors' cost and expense, shall join in the execution of subdivision plats, easements and declarations covering all or any part of the Mortgaged Property and other documents with respect to which Mortgagee's joinder is necessary for the development of the Mortgaged Property as contemplated in the Business Plan, PROVIDED that such subdivision plats, easements, declarations and other documents are in form and substance reasonably satisfactory to Mortgagee and Mortgagors shall have complied in all respects with all applicable provisions of law with respect thereto.", "samples": [{"hash": "iuK6dHMs8h3", "uri": "/contracts/iuK6dHMs8h3#development-matters", "label": "Junior Mortgage and Security Agreement (Atlantic Gulf Communities Corp)", "score": 18.0, "published": true}, {"hash": "h2wWjdKTJdk", "uri": "/contracts/h2wWjdKTJdk#development-matters", "label": "Junior Mortgage and Security Agreement (Atlantic Gulf Communities Corp)", "score": 18.0, "published": true}], "hash": "c65c63061f77726980baf57df392b70e", "id": 3}, {"size": 3, "snippet_links": [{"key": "the-city", "type": "clause", "offset": [4, 12]}, {"key": "approval-of", "type": "definition", "offset": [33, 44]}, {"key": "residential-units", "type": "clause", "offset": [55, 72]}, {"key": "office-uses", "type": "definition", "offset": [113, 124]}, {"key": "the-land", "type": "clause", "offset": [132, 140]}, {"key": "developer-shall", "type": "clause", "offset": [146, 161]}, {"key": "related-to", "type": "definition", "offset": [179, 189]}, {"key": "the-project", "type": "definition", "offset": [205, 216]}, {"key": "comply-with", "type": "definition", "offset": [223, 234]}, {"key": "applicable-rules", "type": "definition", "offset": [239, 255]}, {"key": "otherwise-modified", "type": "clause", "offset": [263, 281]}, {"key": "agreement-or", "type": "definition", "offset": [290, 302]}, {"key": "future-approvals", "type": "clause", "offset": [303, 319]}], "snippet": "(a) The City hereby confirms its approval of up to 531 residential units together with governmental, retail, and office uses within the Land. The Developer shall apply for zoning related to this approval. The Project shall comply with all Applicable Rules unless otherwise modified by this Agreement or future approvals.", "samples": [{"hash": "ewaJ0JPD2KV", "uri": "/contracts/ewaJ0JPD2KV#development-matters", "label": "Agreement Concerning Creation and Operation of Municipal Utility District", "score": 32.7816314697, "published": true}, {"hash": "e9RgwICRjkm", "uri": "/contracts/e9RgwICRjkm#development-matters", "label": "Agreement Concerning Creation and Operation of Municipal Utility District", "score": 32.7460441589, "published": true}, {"hash": "kEnN1pFAVAR", "uri": "/contracts/kEnN1pFAVAR#development-matters", "label": "Agreement Concerning Creation and Operation of Municipal Utility District", "score": 32.7433052063, "published": true}], "hash": "33847c05218fb3f4c9a90a7a40e0a4f6", "id": 4}, {"size": 3, "snippet_links": [{"key": "the-buildings", "type": "clause", "offset": [45, 58]}, {"key": "seller-shall", "type": "clause", "offset": [60, 72]}, {"key": "to-attend", "type": "clause", "offset": [117, 126]}, {"key": "construction-meetings", "type": "clause", "offset": [144, 165]}, {"key": "representatives-of", "type": "clause", "offset": [203, 221]}, {"key": "other-special-meetings", "type": "clause", "offset": [348, 370]}, {"key": "the-construction", "type": "clause", "offset": [456, 472]}, {"key": "in-no-event-shall", "type": "clause", "offset": [491, 508]}, {"key": "provisions-of-this-section", "type": "clause", "offset": [513, 539]}, {"key": "completion-of-the", "type": "clause", "offset": [613, 630]}, {"key": "other-improvements", "type": "definition", "offset": [644, 662]}, {"key": "the-project", "type": "definition", "offset": [666, 677]}, {"key": "subject-to-seller", "type": "definition", "offset": [683, 700]}, {"key": "express-representations", "type": "definition", "offset": [703, 726]}, {"key": "warranties-and-covenants", "type": "clause", "offset": [728, 752]}, {"key": "in-this-agreement", "type": "clause", "offset": [773, 790]}, {"key": "upon-the-closing", "type": "clause", "offset": [792, 808]}, {"key": "and-its-members", "type": "clause", "offset": [865, 880]}, {"key": "employees-and-agents", "type": "clause", "offset": [937, 957]}, {"key": "released-parties", "type": "clause", "offset": [964, 980]}, {"key": "all-claims", "type": "clause", "offset": [1008, 1018]}, {"key": "causes-of-action", "type": "clause", "offset": [1029, 1045]}, {"key": "costs-and-expenses", "type": "clause", "offset": [1114, 1132]}, {"key": "reasonable-attorneys", "type": "definition", "offset": [1144, 1164]}, {"key": "at-any-time", "type": "clause", "offset": [1298, 1309]}, {"key": "arising-out-of", "type": "definition", "offset": [1326, 1340]}, {"key": "construction-defects", "type": "clause", "offset": [1362, 1382]}, {"key": "physical-conditions", "type": "definition", "offset": [1386, 1405]}, {"key": "applicable-laws", "type": "clause", "offset": [1425, 1440]}, {"key": "other-acts", "type": "definition", "offset": [1457, 1467]}, {"key": "the-property", "type": "clause", "offset": [1524, 1536]}, {"key": "all-rights", "type": "clause", "offset": [1586, 1596]}, {"key": "california-civil-code-section-1542", "type": "clause", "offset": [1603, 1637]}, {"key": "general-release", "type": "definition", "offset": [1663, 1678]}, {"key": "at-the-time", "type": "definition", "offset": [1778, 1789]}, {"key": "the-release", "type": "clause", "offset": [1803, 1814]}, {"key": "materially-affected", "type": "definition", "offset": [1855, 1874]}, {"key": "the-debtor", "type": "clause", "offset": [1902, 1912]}, {"key": "the-foregoing-provisions-of-this", "type": "clause", "offset": [1935, 1967]}, {"key": "section-18", "type": "definition", "offset": [1968, 1978]}, {"key": "to-waive-any", "type": "clause", "offset": [2002, 2014]}, {"key": "any-loss", "type": "definition", "offset": [2053, 2061]}, {"key": "to-buyer", "type": "definition", "offset": [2075, 2083]}, {"key": "by-seller", "type": "clause", "offset": [2105, 2114]}, {"key": "breach-of", "type": "definition", "offset": [2134, 2143]}, {"key": "representations-or-warranties", "type": "clause", "offset": [2167, 2196]}, {"key": "the-parties", "type": "clause", "offset": [2290, 2301]}, {"key": "facilities-and-improvements", "type": "clause", "offset": [2377, 2404]}, {"key": "contractors-and-subcontractors", "type": "clause", "offset": [2426, 2456]}, {"key": "seller-will", "type": "clause", "offset": [2480, 2491]}, {"key": "pay-for", "type": "definition", "offset": [2518, 2525]}, {"key": "agreement-or", "type": "definition", "offset": [2748, 2760]}, {"key": "except-to-the-extent", "type": "clause", "offset": [2886, 2906]}, {"key": "the-work", "type": "definition", "offset": [2907, 2915]}, {"key": "employees-of-seller", "type": "clause", "offset": [2938, 2957]}, {"key": "for-avoidance-of-doubt", "type": "clause", "offset": [2983, 3005]}, {"key": "waivers-and-releases", "type": "clause", "offset": [3063, 3083]}, {"key": "third-parties", "type": "definition", "offset": [3137, 3150]}, {"key": "affiliates-of-seller", "type": "clause", "offset": [3164, 3184]}, {"key": "provided-services", "type": "definition", "offset": [3203, 3220]}, {"key": "in-connection-with", "type": "clause", "offset": [3281, 3299]}, {"key": "the-design", "type": "clause", "offset": [3300, 3310]}, {"key": "a-non", "type": "clause", "offset": [3442, 3447]}, {"key": "warranties-and-other-rights", "type": "clause", "offset": [3476, 3503]}, {"key": "all-contractors", "type": "clause", "offset": [3553, 3568]}, {"key": "buyer-will", "type": "clause", "offset": [3678, 3688]}, {"key": "exclusive-right", "type": "clause", "offset": [3700, 3715]}, {"key": "pertaining-to", "type": "definition", "offset": [3819, 3832]}, {"key": "seller-and-buyer", "type": "definition", "offset": [3847, 3863]}, {"key": "acceptance-of", "type": "definition", "offset": [3940, 3953]}, {"key": "provision-of", "type": "clause", "offset": [3969, 3981]}, {"key": "initials-of-buyer", "type": "clause", "offset": [4018, 4035]}], "snippet": "(a) Throughout the period of construction of the Buildings, Seller shall provide Buyer with a reasonable opportunity to attend regular periodic construction meetings between Seller\u2019s representatives and representatives of its contractor(s). To the extent time and convenience permits, Seller also will give Buyer a reasonable opportunity to attend other special meetings between Seller\u2019s representatives and representatives of its contractor(s) concerning the construction of the Buildings. In no event shall the provisions of this Section be allowed to impede or delay the course of development, construction or completion of the Buildings or other improvements at the Project.\n(b) Subject to Seller\u2019s express representations, warranties and covenants set forth elsewhere in this Agreement, upon the Closing Buyer hereby shall waive, relinquish and release Seller and its members and their respective officers, directors, shareholders, employees and agents (the \u201cReleased Parties\u201d) from and against any and all claims, demands, causes of action (including causes of action in tort), losses, damages, liabilities, costs and expenses (including reasonable attorneys\u2019 fees) of any and every kind or character, known or unknown, which Buyer might have asserted or alleged against the Released Parties at any time by reason of or arising out of any latent or patent construction defects or physical conditions, violations of any applicable laws and any and all other acts, omissions, events, circumstances or matters concerning the Property. In connection therewith, Buyer expressly waives all rights under California Civil Code Section 1542, which provides that: \u201cA general release does not extend to claims which the creditor does not know or suspect to exist in his or her favor at the time of executing the release, which if known by him or her must have materially affected his or her settlement with the debtor.\u201d\n(c) Notwithstanding the foregoing provisions of this Section 18, Buyer is not agreeing to waive any claims it may have against Seller for any loss or liability to Buyer to the extent caused by Seller\u2019s acts of fraud or breach of its express covenants, representations or warranties set forth in this Agreement. Buyer specifically acknowledges Seller\u2019s current intention that the parties who will be actually constructing and installing the Buildings and related facilities and improvements will be unaffiliated contractors and subcontractors. Accordingly, although Seller will be obligated to cause and pay for the completion of the Buildings to the extent of obtaining the certifications and inspections as described in Section 14(e) (as applicable) and Section 14(f), thereafter the Released Parties shall not be liable under this Agreement or otherwise for any construction of the Buildings or any defects, deficiencies or other faulty performance pertaining thereto, except to the extent the work has been performed by employees of Seller or Classic Pacific, Ltd. For avoidance of doubt, the parties specifically acknowledge that the foregoing waivers and releases set forth in this Section 18 shall not extend to any third parties that are not affiliates of Seller and that may have provided services or materials to Seller or otherwise have performed any work in connection with the design or construction of the Buildings or related facilities or improvements. Upon the Closing, the Intangibles Assignment shall include a non-exclusive assignment of the warranties and other rights Seller or Classic Pacific, Ltd. may have against all contractors and subcontractors constructing any portion of the Buildings or related facilities or improvements such that Buyer will have a non-exclusive right (along with Seller and Classic Pacific, Ltd.) to enforce such warranties or other rights to the extent pertaining to the Property. Seller and Buyer have each initialed this Section 18 to further indicate their awareness and acceptance of each and every provision of this Section 18. Initials of Seller Initials of Buyer", "samples": [{"hash": "cVIOX1BG3Xd", "uri": "/contracts/cVIOX1BG3Xd#development-matters", "label": "Purchase and Sale Agreement (Cornerstone Core Properties REIT, Inc.)", "score": 19.0, "published": true}, {"hash": "frafLIJDDzp", "uri": "/contracts/frafLIJDDzp#development-matters", "label": "Purchase and Sale Agreement (Cornerstone Core Properties REIT, Inc.)", "score": 17.0, "published": true}], "hash": "ee07a047d1c3f0b83daefd247981735d", "id": 5}, {"size": 2, "snippet_links": [{"key": "execution-date", "type": "definition", "offset": [41, 55]}, {"key": "at-all-times", "type": "definition", "offset": [111, 123]}, {"key": "compliance-with-all-applicable-laws", "type": "clause", "offset": [227, 262]}, {"key": "healthcare-laws", "type": "definition", "offset": [278, 293]}, {"key": "no-company", "type": "clause", "offset": [295, 305]}, {"key": "currently-in", "type": "definition", "offset": [320, 332]}, {"key": "commercial-distribution", "type": "clause", "offset": [333, 356]}, {"key": "by-or-on-behalf-of", "type": "definition", "offset": [357, 375]}, {"key": "knowledge-of-seller", "type": "clause", "offset": [394, 413]}, {"key": "available-to", "type": "definition", "offset": [435, 447]}, {"key": "material-facts", "type": "definition", "offset": [458, 472]}, {"key": "data-and-information", "type": "clause", "offset": [474, 494]}, {"key": "known-to-seller", "type": "definition", "offset": [495, 510]}, {"key": "relating-to", "type": "definition", "offset": [511, 522]}, {"key": "materially-adverse", "type": "definition", "offset": [627, 645]}, {"key": "prior-to-the-closing-date", "type": "clause", "offset": [764, 789]}, {"key": "by-seller-to-buyer", "type": "clause", "offset": [859, 877]}, {"key": "with-respect-to", "type": "clause", "offset": [924, 939]}, {"key": "subject-to", "type": "clause", "offset": [1248, 1258]}, {"key": "any-notice", "type": "clause", "offset": [1259, 1269]}, {"key": "administrative-proceeding", "type": "definition", "offset": [1280, 1305]}, {"key": "communication-of", "type": "clause", "offset": [1342, 1358]}, {"key": "has-violated", "type": "definition", "offset": [1459, 1471]}, {"key": "to-the-company", "type": "definition", "offset": [1499, 1513]}, {"key": "program-assets", "type": "clause", "offset": [1527, 1541]}, {"key": "no-person", "type": "definition", "offset": [1571, 1580]}, {"key": "to-file", "type": "definition", "offset": [1609, 1616]}, {"key": "any-action", "type": "definition", "offset": [1659, 1669]}, {"key": "or-equivalent", "type": "definition", "offset": [1719, 1732]}, {"key": "applicable-jurisdiction", "type": "clause", "offset": [1744, 1767]}, {"key": "clinical-investigator", "type": "definition", "offset": [1846, 1867]}, {"key": "convicted-of", "type": "definition", "offset": [1918, 1930]}, {"key": "engaged-in", "type": "definition", "offset": [1944, 1954]}, {"key": "work-related", "type": "clause", "offset": [2139, 2151]}, {"key": "being-conducted", "type": "definition", "offset": [2249, 2264]}, {"key": "in-connection-with", "type": "clause", "offset": [2300, 2318]}, {"key": "good-laboratory-practices", "type": "clause", "offset": [2417, 2442]}, {"key": "corrective-action-plans", "type": "clause", "offset": [2501, 2524]}, {"key": "clinical-trials", "type": "clause", "offset": [2529, 2544]}, {"key": "each-case", "type": "definition", "offset": [2652, 2661]}, {"key": "company-compound", "type": "definition", "offset": [2676, 2692]}, {"key": "no-governmental-entity", "type": "clause", "offset": [2785, 2807]}, {"key": "notice-to", "type": "definition", "offset": [2828, 2837]}, {"key": "any-other-person", "type": "definition", "offset": [2838, 2854]}, {"key": "by-the-company", "type": "clause", "offset": [2991, 3005]}], "snippet": "(a) All Kv7 Compounds existing as of the Execution Date (collectively, the \u201cCompany Compounds\u201d) are being, and at all times have been, developed, tested, processed, manufactured, stored, and shipped, as applicable, in material compliance with all applicable Laws, including all Healthcare Laws. No Company Compounds are currently in commercial distribution by or on behalf of Seller, or to the Knowledge of Seller.\n(b) Seller has made available to Buyer all material facts, data and information known to Seller relating to the efficacy, toxicity, stability, synthesis and selectivity of [**].\n(c) No facts, data or information materially adverse to the Kv7 Discovery Platform and known to Seller have been omitted from disclosures made to Buyer and its Affiliates prior to the Closing Date.\n(d) All analyses, presentations and results that have been provided by Seller to Buyer and its Affiliates were unbiased and complete with respect to the efficacy, toxicity, stability, synthesis and selectivity of [**].\n(e) Any facts, data or information materially adverse to the Kv7 Discovery Platform and known to Seller have been specifically identified and disclosed to Buyer or its Affiliates.\n(f) Seller and its Subsidiaries have not received or been subject to any notice, warning, administrative proceeding, order, complaint, or other written communication of any actual or threatened Action, investigation or allegation that Seller or any of its Subsidiaries has violated any applicable Law related to the Company Compounds or Program Assets. To the Knowledge of Seller, no Person has filed or has threatened to file against Seller or any of its Subsidiaries any Action under any federal or state whistleblower statute or equivalent Law in the applicable jurisdiction. None of Seller or any of its Subsidiaries or any officer, employee, agent or clinical investigator thereof has been suspended, debarred, excluded or convicted of any crime or engaged in any conduct that would reasonably be expected to result in debarment under 21 U.S.C. Section 335a, exclusion under 42 U.S.C. Section 1320a-7 or any similar Action.\n(g) All preclinical work related to the Company Compounds sponsored or conducted by Seller and its Subsidiaries have been and are being conducted in, and all Company Compounds used in connection with such investigations are and have been in, material compliance with all applicable Laws, including Good Laboratory Practices, other Healthcare Laws, applicable research protocols and corrective action plans. No clinical trials are being or have been sponsored or conducted by or on behalf of Seller, or to the Knowledge of Seller, in each case involving any Company Compound. Seller and its Subsidiaries have not received any notice from any Governmental Entity, and no Governmental Entity has issued any such notice to any other Person that any Company Compound cannot be developed, investigated, or shipped substantially in the manner presently performed or contemplated by the Company.", "samples": [{"hash": "11udrrvT1QO", "uri": "/contracts/11udrrvT1QO#development-matters", "label": "Membership Interest Purchase Agreement (Biohaven Research Ltd.)", "score": 33.6050643921, "published": true}, {"hash": "8rxqdiR4JJO", "uri": "/contracts/8rxqdiR4JJO#development-matters", "label": "Membership Interest Purchase Agreement (Biohaven Pharmaceutical Holding Co Ltd.)", "score": 33.3531837463, "published": true}], "hash": "f5586fc1759c5622bff7ca203e9578d1", "id": 6}, {"size": 2, "snippet_links": [{"key": "the-obligation", "type": "clause", "offset": [46, 60]}, {"key": "development-activities", "type": "clause", "offset": [77, 99]}, {"key": "with-respect-to", "type": "clause", "offset": [101, 116]}, {"key": "in-the-field", "type": "clause", "offset": [140, 152]}, {"key": "in-the-territory", "type": "clause", "offset": [153, 169]}, {"key": "service-provider", "type": "definition", "offset": [242, 258]}], "snippet": "AnaptysBio shall have the sole right, but not the obligation, to conduct all Development activities, with respect to Compounds and Products in the Field in the Territory, whether itself, or by or through or with any Affiliate, Sublicensee or Service Provider. 5.2", "samples": [{"hash": "33uu6cxbXuP", "uri": "/contracts/33uu6cxbXuP#development-matters", "label": "License Agreement (Anaptysbio, Inc)", "score": 33.1902809143, "published": true}], "hash": "b55ae52e2352a6a366fee830e9b6ae72", "id": 7}, {"size": 2, "snippet_links": [{"key": "landlord-shall", "type": "clause", "offset": [43, 57]}, {"key": "to-third-parties", "type": "clause", "offset": [128, 144]}, {"key": "adjacent-to", "type": "definition", "offset": [289, 300]}, {"key": "shopping-center", "type": "clause", "offset": [305, 320]}, {"key": "equitable-title", "type": "clause", "offset": [339, 354]}, {"key": "by-landlord", "type": "clause", "offset": [367, 378]}, {"key": "at-any-time", "type": "clause", "offset": [379, 390]}, {"key": "during-the-term", "type": "clause", "offset": [391, 406]}, {"key": "independent-developments", "type": "clause", "offset": [488, 512]}, {"key": "the-understanding", "type": "clause", "offset": [560, 577]}, {"key": "in-the-event-of-a", "type": "clause", "offset": [776, 793]}, {"key": "landlord-may-enter", "type": "clause", "offset": [852, 870]}, {"key": "an-agreement", "type": "clause", "offset": [876, 888]}, {"key": "the-transferee", "type": "clause", "offset": [894, 908]}, {"key": "other-rights", "type": "clause", "offset": [943, 955]}, {"key": "other-matters", "type": "definition", "offset": [977, 990]}, {"key": "as-landlord", "type": "definition", "offset": [991, 1002]}, {"key": "to-the-extent", "type": "clause", "offset": [1034, 1047]}, {"key": "landlord-and-tenant-hereby", "type": "clause", "offset": [1091, 1117]}, {"key": "to-sell", "type": "clause", "offset": [1173, 1180]}, {"key": "a-separate", "type": "definition", "offset": [1249, 1259]}, {"key": "balance-of-the", "type": "clause", "offset": [1666, 1680]}], "snippet": "Tenant hereby agrees and acknowledges that Landlord shall be permitted to improve or cause to be improved or to convey or lease to third parties for improvement (without the necessity of obtaining Tenant\u2019s consent) the outlots, if any, depicted on EXHIBIT \u201cB-1\u201d, or any lots contiguous or adjacent to the Shopping Center to which legal or equitable title is acquired by Landlord at any time during the term hereof (individually, an \u201cOutlot\u201d, collectively, the \u201cOutlots\u201d), as separate and independent developments from the remainder of the Shopping Center with the understanding that the Outlots and the remainder of the Shopping Center shall nevertheless constitute an integrated shopping center and the same may not, at Landlord\u2019s election, form part of the Shopping Center. In the event of a sale, transfer or other conveyance of any of the Outlots, Landlord may enter into an agreement with the transferee granting appropriate easement and other rights, and containing such other matters as Landlord and such transferee may agree, to the extent not inconsistent with this Lease. Further, Landlord and Tenant hereby agree and acknowledge that Landlord shall be permitted to sell, transfer or otherwise convey any portion of the Shopping Center as a separate and independent development from the remainder of the Shopping Center with the understanding that any such portion and the remainder of the Shopping Center shall nevertheless constitute an integrated shopping center and the same may not, at Landlord\u2019s election, form part of the Shopping Center. In the event of a sale, transfer or other conveyance of any portion of the Shopping Center (separate from the balance of the Shopping Center), Landlord may enter into an agreement with the transferee granting appropriate easement and other rights, and containing such other matters as Landlord and such transferee may agree, to the extent not inconsistent with this Lease.", "samples": [{"hash": "kASGDTVH7PV", "uri": "/contracts/kASGDTVH7PV#development-matters", "label": "Multi Tenant Office Lease Agreement (Pluralsight, Inc.)", "score": 28.9671459198, "published": true}], "hash": "235595564078ec40517be9f40a48f4ba", "id": 8}, {"size": 1, "snippet_links": [{"key": "in-connection-with", "type": "clause", "offset": [0, 18]}, {"key": "development-of-the-property", "type": "clause", "offset": [23, 50]}, {"key": "residential-lots", "type": "definition", "offset": [70, 86]}, {"key": "seller-and-purchaser", "type": "clause", "offset": [153, 173]}, {"key": "the-land", "type": "clause", "offset": [196, 204]}], "snippet": "In connection with the development of the Property into single-family residential lots, Purchaser shall name three (3) streets in a manner acceptable to Seller and Purchaser to honor and remember the land owners of over sixty (60) years.", "samples": [{"hash": "3Lo485oPjmP", "uri": "/contracts/3Lo485oPjmP#development-matters", "label": "Purchase and Sale Agreement (Maple X, Inc.)", "score": 31.5065021515, "published": true}], "hash": "3598228730a9b6b546ffd994954598bd", "id": 9}, {"size": 1, "snippet_links": [{"key": "company-responsibilities", "type": "clause", "offset": [4, 28]}, {"key": "development-period", "type": "definition", "offset": [48, 66]}, {"key": "responsible-for", "type": "clause", "offset": [128, 143]}, {"key": "company-development-activities", "type": "clause", "offset": [176, 206]}, {"key": "the-designated", "type": "clause", "offset": [245, 259]}, {"key": "clinical-trials", "type": "clause", "offset": [260, 275]}, {"key": "authority-of-the", "type": "clause", "offset": [292, 308]}, {"key": "with-respect-to", "type": "clause", "offset": [313, 328]}, {"key": "critical-matters", "type": "definition", "offset": [329, 345]}, {"key": "in-good-faith", "type": "clause", "offset": [438, 451]}, {"key": "regarding-the-company", "type": "clause", "offset": [523, 544]}, {"key": "costs-and-liabilities", "type": "clause", "offset": [650, 671]}, {"key": "to-amgen", "type": "clause", "offset": [681, 689]}, {"key": "indemnification-obligations", "type": "definition", "offset": [692, 719]}, {"key": "section-132", "type": "clause", "offset": [732, 744]}, {"key": "associated-with", "type": "definition", "offset": [746, 761]}, {"key": "conduct-of-the-company", "type": "clause", "offset": [766, 788]}, {"key": "for-clarity", "type": "clause", "offset": [820, 831]}, {"key": "liabilities-incurred", "type": "clause", "offset": [855, 875]}, {"key": "by-or-on-behalf-of", "type": "definition", "offset": [876, 894]}, {"key": "agreement-or", "type": "definition", "offset": [1003, 1015]}, {"key": "assistance-to-company", "type": "clause", "offset": [1036, 1057]}, {"key": "contemplated-by-this-agreement", "type": "clause", "offset": [1061, 1091]}, {"key": "from-the-effective-date", "type": "clause", "offset": [1094, 1117]}, {"key": "payment-of-the", "type": "clause", "offset": [1148, 1162]}, {"key": "development-milestone", "type": "definition", "offset": [1171, 1192]}, {"key": "complete-and-accurate-records", "type": "clause", "offset": [1213, 1242]}, {"key": "pertaining-to", "type": "definition", "offset": [1266, 1279]}, {"key": "by-company", "type": "clause", "offset": [1315, 1325]}, {"key": "in-aggregate", "type": "definition", "offset": [1431, 1443]}, {"key": "development-costs", "type": "definition", "offset": [1458, 1475]}, {"key": "the-right", "type": "clause", "offset": [1600, 1609]}, {"key": "written-notice-to-company", "type": "clause", "offset": [1631, 1656]}, {"key": "an-independent", "type": "clause", "offset": [1686, 1700]}, {"key": "public-accounting", "type": "clause", "offset": [1726, 1743]}, {"key": "to-the-company", "type": "definition", "offset": [1818, 1832]}, {"key": "normal-business-hours", "type": "definition", "offset": [1868, 1889]}, {"key": "purpose-of", "type": "clause", "offset": [1899, 1909]}, {"key": "the-accounting-firm", "type": "clause", "offset": [1966, 1985]}, {"key": "company-only", "type": "clause", "offset": [2004, 2016]}, {"key": "reported-company", "type": "definition", "offset": [2029, 2045]}, {"key": "specific-details", "type": "clause", "offset": [2097, 2113]}, {"key": "no-other-information", "type": "clause", "offset": [2144, 2164]}, {"key": "a-copy-of", "type": "clause", "offset": [2240, 2249]}, {"key": "and-company", "type": "clause", "offset": [2291, 2302]}, {"key": "opportunity-to-discuss", "type": "clause", "offset": [2317, 2339]}, {"key": "confidential-information-of-company", "type": "clause", "offset": [2484, 2519]}, {"key": "obligations-of", "type": "clause", "offset": [2561, 2575]}, {"key": "amgen-responsibilities", "type": "clause", "offset": [2593, 2615]}, {"key": "use-commercially-reasonable-efforts", "type": "clause", "offset": [2740, 2775]}, {"key": "company-in", "type": "clause", "offset": [3352, 3362]}, {"key": "performance-of-the-company", "type": "clause", "offset": [3367, 3393]}, {"key": "notwithstanding-anything-to-the-contrary", "type": "clause", "offset": [3556, 3596]}, {"key": "in-this-agreement", "type": "clause", "offset": [3597, 3614]}, {"key": "to-amend", "type": "definition", "offset": [3679, 3687]}, {"key": "the-development-plan", "type": "clause", "offset": [3688, 3708]}, {"key": "the-sponsorship", "type": "clause", "offset": [3833, 3848]}, {"key": "clinical-study", "type": "definition", "offset": [3866, 3880]}, {"key": "provided-that", "type": "definition", "offset": [3883, 3896]}, {"key": "following-the", "type": "definition", "offset": [4178, 4191]}, {"key": "subject-to-sections", "type": "clause", "offset": [4262, 4281]}, {"key": "right-to-develop", "type": "clause", "offset": [4321, 4337]}, {"key": "the-products", "type": "clause", "offset": [4338, 4350]}, {"key": "in-the-event", "type": "clause", "offset": [4482, 4494]}, {"key": "to-pay", "type": "clause", "offset": [4513, 4519]}, {"key": "efforts-to-obtain", "type": "clause", "offset": [4592, 4609]}, {"key": "regulatory-approval", "type": "clause", "offset": [4610, 4629]}, {"key": "for-products", "type": "clause", "offset": [4630, 4642]}, {"key": "major-markets", "type": "definition", "offset": [4690, 4703]}], "snippet": "(a) Company Responsibilities during the Company Development Period.\n(i) During the Company Development Period, Company shall be responsible for, and shall conduct, each of the Company Development Activities, including sponsorship and conduct of the Designated Clinical Trials. Subject to the authority of the JPT with respect to Critical Matters, during the Company Development Period, Company shall reasonably consult with, and consider in good faith any input provided by, Amgen regarding any material plans or decisions regarding the Company Development Activities.\n(ii) During the Company Development Period, Company shall be responsible for all costs and liabilities (subject to Amgen\u2019s indemnification obligations pursuant to Section 13.2) associated with the conduct of the Company Development Activities (which, for clarity, excludes any costs or liabilities incurred by or on behalf of Amgen in its performance of the Amgen Development Activities, its performance of its obligations under this Agreement or in its provision of assistance to Company as contemplated by this Agreement). From the Effective Date until two (2) years after the payment of the Company Development Milestone, Company shall keep complete and accurate records, in reasonable detail, pertaining to the costs and liabilities incurred by Company associated with the conduct of the Company Development Activities (such documented costs and liabilities in aggregate, the \u201cCompany Development Costs\u201d).\n(i) From the Effective Date until two (2) years after the payment of the Company Development Milestone, Amgen shall have the right, upon 30 days\u2019 prior written notice to Company, to cause, at Amgen\u2019s costs, an independent, certified international public accounting firm reasonably acceptable to Company to audit Company\u2019s records relating to the Company Development Costs during Company\u2019s normal business hours with the purpose of confirming the amount of the Company Development Costs. The accounting firm shall disclose to Company only whether the reported Company Development Costs are correct or incorrect and the specific details concerning any discrepancies. No other information shall be provided to Amgen. The accounting firm shall provide Company with a copy of any disclosures or reports made to Amgen and Company shall have an opportunity to discuss such disclosures or reports with Amgen and the accounting firm. Information, disclosures, or reports arising from any such examination shall be Confidential Information of Company subject to the confidentiality and other obligations of Article \u200e11.\n(b) Amgen Responsibilities during the Company Development Period.\n(i) During the Company Development Period, Amgen shall be responsible for, and shall use Commercially Reasonable Efforts to conduct, each of the Amgen Development Activities. Subject to the authority of the JPT with respect to Critical Matters, during the Company Development Period, Amgen shall reasonably consult with, and consider in good faith any input provided by, Company regarding any material plans or decisions regarding the Amgen Development Activities.\n(ii) During the Company Development Period, Amgen shall be responsible for all costs associated with the conduct of the Amgen Development Activities (which, for clarity, excludes any costs or liabilities incurred by or on behalf of Company in its performance of the Company Development Activities, its performance of its obligations under this Agreement or its provision of assistance to Amgen as contemplated by this Agreement).\n(iii) Notwithstanding anything to the contrary in this Agreement, during the Company Development Period, Amgen shall be entitled to amend the Development Plan to allow Amgen or its Affiliates or Sublicensees to conduct any development activities with respect to a Product (including the sponsorship and conduct of a clinical study), provided that (A) Amgen shall be responsible for all costs associated with such activities and that such activities shall be deemed Amgen Development Activities and (B) Amgen shall not unreasonably disregard input from Provention on such Amgen Development Activities.\n(c) Amgen Responsibilities following the Company Development Period. Following the Company Development Period, subject to Sections 3.2 and 3.3, Amgen shall have the sole right to develop the Products. Following the Company Development Period, Amgen shall bear all costs associated with development activities relating to Products. In the event that Amgen elects to pay the Company Development Milestone, it shall use Commercially Reasonable Efforts to obtain Regulatory Approval for Products for the NRCD Indication in at least one of the Major Markets and thereafter to Exploit Products in at least one of the Major Markets.", "samples": [{"hash": "icJn8JfkFtW", "uri": "/contracts/icJn8JfkFtW#development-matters", "label": "License and Collaboration Agreement (Provention Bio, Inc.)", "score": 30.2101306915, "published": true}], "hash": "4a932d3c6226b3e66ec8c92d84b8dc33", "id": 10}], "next_curs": "ClwSVmoVc35sYXdpbnNpZGVyY29udHJhY3RzcjgLEhZDbGF1c2VTbmlwcGV0R3JvdXBfdjU2IhxkZXZlbG9wbWVudC1tYXR0ZXJzIzAwMDAwMDBhDKIBAmVuGAAgAA==", "clause": {"size": 90, "parents": [["development-and-regulatory", "Development and Regulatory"], ["representations-and-warranties-of-the-company", "REPRESENTATIONS AND WARRANTIES OF THE COMPANY"], ["development-matters", "Development Matters"], ["miscellaneous", "Miscellaneous"], ["miscellaneous-provisions", "Miscellaneous Provisions"]], "title": "Development Matters", "children": [["schedule-of-performance", "Schedule of Performance"], ["generally", "Generally"], ["development-plan", "Development Plan"], ["permitted-variances-to-city-development-requirements", "Permitted Variances to City Development Requirements"], ["development-completion", "Development; Completion"]], "id": "development-matters", "related": [["patent-matters", "Patent Matters", "Patent Matters"], ["research-matters", "Research Matters", "Research Matters"], ["development-activities", "Development Activities", "Development Activities"], ["development-and-commercialization", "Development and Commercialization", "Development and Commercialization"], ["collaboration-activities", "Collaboration activities", "Collaboration activities"]], "related_snippets": [], "updated": "2026-05-16T04:22:31+00:00", "also_ask": [], "drafting_tip": null, "explanation": "The \"Development Matters\" clause outlines the obligations and considerations related to the development phase of a project or product. It typically addresses issues such as timelines, milestones, deliverables, and the responsibilities of each party during development. For example, it may specify how progress will be tracked, what constitutes completion of a development stage, or how changes to the development plan are managed. The core function of this clause is to ensure that both parties have a clear understanding of the development process, reducing the risk of misunderstandings and disputes regarding project progress and expectations."}, "json": true, "cursor": ""}}